Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026494 · ClinicalTrials.gov registry record · Phase 1
Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00026494: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00026494 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026494, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who have recurrent brain metastases.
Interventions
- DRUG temozolomide
- DRUG vinorelbine tartrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2001-07 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026494
The ClinicalTrials.gov registry entry for NCT00026494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which temozolomide is the first listed.
NCT00026494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026494 about?
NCT00026494 is a clinical study titled "Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide and vinorelbine in treating patients who have recurrent brain metastases.
What is the current status of trial NCT00026494?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2001-07. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00026494?
The interventions under investigation include: temozolomide (DRUG), vinorelbine tartrate (DRUG).
Who is sponsoring clinical trial NCT00026494?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.